Check for updates

REVIEW

Effect of antibiotics on bacterial populations: a multi-hierarchical selection process [version 1; peer review: 2 approved]

José Luis Martínez

Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas, Calle Darwin, Madrid, Spain

V1 First published: 17 Jan 2017, 6(F1000 Faculty Rev):51
<https://doi.org/10.12688/f1000research.9685.1>

Latest published: 17 Jan 2017, 6(F1000 Faculty Rev):51
<https://doi.org/10.12688/f1000research.9685.1>

Abstract

Antibiotics have been widely used for a number of decades for human therapy and farming production. Since a high percentage of antibiotics are discharged from the human or animal body without degradation, this means that different habitats, from the human body to river water or soils, are polluted with antibiotics. In this situation, it is expected that the variable concentration of this type of microbial inhibitor present in different ecosystems may affect the structure and the productivity of the microbiota colonizing such habitats. This effect can occur at different levels, including changes in the overall structure of the population, selection of resistant organisms, or alterations in bacterial physiology. In this review, I discuss the available information on how the presence of antibiotics may alter the microbiota and the consequences of such alterations for human health and for the activity of microbiota from different habitats.

Keywords

antibiotic resistance, antibiotic, antibiotic-resistant mutants, antibiotic stress, clostridium difficile, mobile genetic element, microbiome, subinhibitory concentrations of antibiotics, biofilm

Open Peer Review

Approval Status

	1	2
version 1
17 Jan 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Søren Molin**, Danmarks Tekniske Universitet, Lyngby, Denmark
2. **Ivan Matic**, Université Paris Descartes, Paris, France

Any comments on the article can be found at the end of the article.

Corresponding author: José Luis Martínez (jlmtnez@cnb.csic.es)

Competing interests: The author declares that he has no competing interests.

Grant information: The author's laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness (BIO2014-54507-R and JPI Water StARE JPIW2013-089-C02-01) and from the Instituto de Salud Carlos III (Spanish Network for Research on Infectious Diseases [RD16/0016/0011]).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Martínez JL. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Martínez JL. **Effect of antibiotics on bacterial populations: a multi-hierarchical selection process [version 1; peer review: 2 approved]** F1000Research 2017, 6(F1000 Faculty Rev):51 <https://doi.org/10.12688/f1000research.9685.1>

First published: 17 Jan 2017, 6(F1000 Faculty Rev):51 <https://doi.org/10.12688/f1000research.9685.1>

Introduction

Antibiotics are among the most successful drugs used in human therapy. In addition, they have been used for several decades in animal growth promotion, prophylaxis, metaphylaxis, treatment, and general farming production^{1–4}. This wide antibiotic use has led to different habitats becoming polluted by a large range of concentrations of antibiotics⁵. Since antibiotics are inhibitors of bacterial growth, this situation has an impact on the structure and the activity of bacterial populations. The effect of antibiotics on bacterial populations has mainly focused on the aspects related to human health, in particular the selection of antibiotic-resistant mutants and the acquisition, selection, and spread of antibiotic resistance genes^{6–8}. While this has obvious relevance to the treatment of infectious diseases, other aspects of the roles that antibiotics may play in bacterial populations are much less studied in comparison^{9,10}. In the field of human health, some studies have addressed the impact of antibiotic treatment on the global structure of the human gut microbiome^{11–18}. These articles focus particularly on the general description of changes at the population level as well as on the selection of resistance genes. However, with recent work considering the gut microbiome itself as an organ, and taking into consideration that microbial composition may impact human physiology at different levels, more information on the consequences that changes to the human microbiome in the presence of antibiotics have on human health is still needed^{19–22}. One aspect to be taken into consideration is that, when antibiotic treatment is needed, the effects of the antimicrobial on the microbiome should be considered as unavoidable side effects. Nevertheless, some work indicates that these effects can be mitigated by using compounds able to adsorb antibiotics in the gut²³. By using these compounds together with antibiotics, the concentration of the drug at the point of infection (unless in gut infections) will not change; however, it will be much lower at the gut and the microbiome should not be strongly altered.

One aspect that has received more attention in the last few years is the effect of antibiotics in environmental microbiota^{5,9,24}. Also, in this case, most studies focus on the aspects of this topic closer to human health, in particular how natural ecosystems, polluted or not with antibiotics, may be involved in the acquisition, selection, and spread of antibiotic resistance among human pathogens^{9,24–30}. This “one-health” approach is, of course, needed if we wish to fully understand the spread and maintenance of clinically relevant antibiotic-resistant microorganisms³¹. Nevertheless, it is worth mentioning that fewer studies focus on the overall effect of antibiotics on the structure and productivity of environmental, not pathogenic, bacteria. Taking into consideration that all basic nutrient cycles in nature (carbon, nitrogen, oxygen, etc.) are based on the metabolism of microorganisms, learning whether or not antibiotic pollution may alter the right functioning of these cycles is of relevance. However, only some studies have addressed this relevant topic^{32–35}. It is true that the concentrations of antibiotics are low in most ecosystems, but even low concentrations of antibiotics may trigger specific bacterial responses^{36–39}, and analyzing such responses is a topic of interest.

In this review, I will discuss the multiple levels at which the presence of antibiotics may alter the structure of bacterial populations. Although the focus of the review will be the impact of such changes

on human health, other more general aspects of the topic will be discussed as well.

Antibiotics, natural compounds, and pollutants

Humankind has been using antimicrobial compounds for treating infections even before the discovery of microorganisms. However, these compounds did not belong to the type of chemical entities that are now known as antibiotics. Compounds such as mercury, lead, silver, or arsenic derivatives have been widely used. Even when the search for antimicrobials focused directly on inhibitors of microorganisms, the first industrially produced antibiotic was an organic derivative of arsenic, salvarsan. The first natural antibiotic was penicillin. However, the idea that soil (and water) can be a source of antimicrobials came from an ecological reflection: if soils are constantly polluted by pathogenic microorganisms, but soils are not a source of epidemics, there must be something in soils capable of killing human bacterial pathogens. This approach, proposed by Waskman and Woodruff⁴⁰, led to the identification of most of the antibiotic families currently in use in clinical practice. Indeed, although several natural antibiotics are chemically modified to improve their efficacy, few families, such as quinolones, have a synthetic origin, and even in this case, natural quinolones, some of them involved in cell-to-cell communication⁴¹, have been found. Differing to xenobiotic compounds, which were not previously present in nature and can be refractory for their biodegradation, natural antibiotics are degradable. In addition, some microorganisms can subsist using antibiotics as a food resource⁴². Since antibiotics are natural compounds, pollution by these drugs and the effect they have on bacterial populations are concentration-dependent problems. It is worth mentioning that we include under the name of antibiotics just those compounds that are useful for treating infections – in other words, those bacterial inhibitors without problems of toxicity and with pharmacokinetic/pharmacodynamic properties that allow their use in clinics. This does not necessarily mean that antibiotics are always inhibitors of microbial competitors at the low concentrations that they are naturally produced³⁸. Conversely, different microbial-produced compounds without the pharmacological properties required for treating an infection may serve in nature to inhibit the growth of competitors. Under this circumstance, it has been proposed that the effect of antibiotics on bacterial populations can be hormetic^{43–45} in character, beneficial at low concentrations and deleterious at the high ones usually present inside patients during treatment^{38,46}. Distinguishing between these two situations is then critical for understanding the effect of antibiotics on bacterial populations.

Multi-hierarchical antibiotic selection of bacterial populations

Since antibiotics are naturally produced compounds, it is expected that environmental microbial populations have adapted along their evolution to the presence of the natural concentrations of these antimicrobials⁴⁷. However, the constant discharge of antibiotics in nature may alter this homeostasis. Particularly important are the allocations in which antibiotic concentrations are higher: treated patients and animals. Other habitats in which high-level concentrations of antibiotics (and of resistance genes) can be found are waste-water treatment plants or rivers receiving domestic, hospital, farm, and industrial waters, soil at farms, water and sludge at fish farms, and manure^{5,48}. In all cases, antibiotics can affect the

structure of bacterial populations at different levels. First will be the population composition itself. Any bacterial species has a characteristic level of susceptibility to any given antimicrobial, which has been dubbed “intrinsic resistance”^{49–51}. This means that, for any given concentration of antibiotic, a part of the population present in the microbiota (the most susceptible one) will be inhibited and another part will consequently increase their abundance. It is expected that a strong stressor (such as the presence of an antibiotic) will reduce diversity^{28,52}, and this is likely to be true when the concentrations of the inhibitor are high. However, mild concentrations of antibiotics may produce an apparent increase in biodiversity, or at least the emergence of new taxons whose presence was minor before antibiotic stress⁵³, if the most predominant species present in the microbiome are susceptible and hence inhibited by such concentrations. The most detailed studies of the effect of antibiotics on the global composition of the microbiota have been performed studying the gut microbiota of humans and of experimental mammal models as well^{11,12,16,18}. In all cases, a misbalance in the composition is observed upon treatment. Once treatment ends, a recovery of the composition of the microbiome is observed after some time. However, recent information indicates that, although the structure of the taxonomic groups is similar three months after treatment to the one observed before antibiotic application¹³, the specific clones that re-colonize the gut are not the same as those before treatment. This means that while the overall structure of the population remains, the overall genomic content largely varies¹³. These results indicate that the effect of antibiotics on the structure of the populations will remain long after they disappear from the polluted habitat. The disruption of the system as a consequence of antibiotic use can be followed by its reconstruction by an eco-equivalent microbiome. However, it does not mean that the functionality of the new clones is the same as the previous ones, a feature that may be of relevance for not only human health but also the productivity and biodegradative potential of environmental microbial populations.

At very high concentrations of antibiotics, the system may collapse and can be open for colonization by antibiotic-resistant microorganisms that otherwise would not be present in this ecosystem. This is the situation with *Clostridium difficile*, a major cause of gut infection in individuals following antibiotic treatment^{54,55} and whose infection is associated with a reduction in gut microbiota diversity⁵⁶. Given *C. difficile*'s low susceptibility to antibiotics, the best way for fighting recurrent infections caused by this pathogen is restoring the functionality of the gut microbiota via fecal transplantation^{57–60}.

In addition to altering the overall structure of bacterial populations, the best-studied effect of antibiotics is the selection of antibiotic-resistant microorganisms. As stated above, selecting for intrinsic resistance will modify the taxonomic structure of a given ecosystem. Differing to that situation, the selection of mutants or bacteria carrying resistance genes acquired through horizontal gene transfer (HGT) will enrich some specific lineages that have acquired resistance. Here it is important to distinguish between mutation-driven and HGT-acquired resistance. The first is just vertically inherited and hence allows clonal expansion, whereas the second can be transferred both vertically and horizontally and hence can spread among the global population. In the case of HGT-driven

resistance, different levels of selection can be foreseen. The gene is selected by the antibiotic, which produces the selection of the mobile genetic element (MGE) carrying it, the clone carrying the plasmid, and eventually the gene-exchange community to which this clone belongs if the resistance element spreads among its members^{61–63}. As the consequence of this second-order selection, antibiotics may increase the success of some species and even of some specific clones in the community, somehow altering the overall physiology of the microbiome through the selection of a set of clones and genes. In this regard, it is worth mentioning that the number of genes present in nature and capable of conferring resistance upon their transfer to a heterologous host is several orders of magnitude larger than those currently found in human pathogens^{64,65}. The human use of antibiotics has produced an explosive enrichment of a few so-called resistance genes present in MGEs, and now these are widespread all around the world⁶⁶.

Short-term and long-term effects of antibiotics in bacterial populations

As stated above, antibiotics can alter the population structure of the microbiome (immediate effect), and while the overall structure of such microbiomes is recovered after some (usually a long) time, the genomic structure is not fully equivalent. As in the case of other strong stressors, this could be predicted; once an organism has been displaced, the same one will rarely re-colonize the habitat. This is not particularly relevant in the case of multicellular organisms. If a fire destroys a pine forest, obviously different pines will re-colonize the soil, but this does not have an impact on the overall activity of the system. However, in the case of microorganisms, the situation is dramatically different. Bacteria present a core genome that is shared by all members of the species and an accessory genome that is specific to each member of the species. The first encodes the most basic processes of the organism, and the second encodes the most adaptive ones: for instance, those that make the commensal bacteria *Escherichia coli* become a dangerous pathogen, those dealing with antibiotic resistance, or several involved in the biodegradation of toxic compounds. In this regard, although the basic activities encoded in the core genome will be restored, other activities can be lost when one clone is replaced by another. As stated, this situation is relevant for human health but can also be of relevance in other habitats such as waste-water treatment plants, where degradative bacteria can be important^{33,53}. Current metagenomic techniques allow a broad taxonomic analysis of the populations as well as of the presence of specific genes in the microbiome. However, although some strategies have been implemented^{67–73}, studies on genome reconstruction as well as gene-taxon binning (mainly in the case of mobile elements) are not easy to perform using currently available tools, at least in complex microbiota, which are the most frequently found. Under these circumstances, full information on the long-term effect of antibiotics in microbiome composition at the clonal level is still lacking.

Another (and better-studied) effect of antibiotics is the selection of antibiotic-resistant microorganisms. In this case, antibiotic pollution selects a set of mutants or genes (antibiotic resistance genes) that can be considered as pollutants themselves^{66,74} because they were not present (at least at the level they are now) in nature. The main difference between classical pollutants and resistant bacteria (or any type of microorganism at large) is that the first disappear

over time and across space, whereas microorganisms and resistance genes are auto-replicative pollutants that can travel across long distances and remain over time⁷⁵. It has been proposed that the acquisition of antibiotic resistance confers a fitness cost that is reflected in a lower competitiveness of the resistant microorganisms as compared with the susceptible one^{76,77}. While this is true on occasion, it has been shown that antibiotic resistance might not reduce fitness but can even increase bacterial competitiveness^{77,78}. On top of that, resistant microorganisms can acquire compensatory mutations or physiological changes that restore their fitness^{79–81}. Upon these conditions, it is not rare that bacteria carrying resistance genes are found in nearly any tested habitat, including domestic and wild animals, natural ecosystems, or untreated human volunteers, such as isolated Yanomami Amerindians, among others^{82–92}. Human travel, interchanging of goods, climate alterations such as El Niño, and migratory birds, among other vectors, allow the intercontinental distribution of the auto-replicative pollutants that are antibiotic resistance and antibiotic resistance genes^{93–97}.

While the acquisition of resistance may have the same ecological consequences for a human pathogen or for a non-pathogenic environmental microorganism, the consequences for human health are very different. Mutation-driven resistance is not a health risk if the resistant microorganism is not pathogenic. However, the acquisition of a resistance gene by an MGE is a risk for human health even when the MGE is present in an environmental microorganism^{64,65}. It is important to remark that resistance genes currently present in MGEs were not present in human pathogens before the industrial production of antibiotics⁹⁸; they have originated from environmental microorganisms^{99–101}. The farm-animal-to-human transfer of resistance has been discussed in detail, and farm animals are considered to be a reservoir of antibiotic resistance². Since the use of antibiotics for fish-farming challenges the fish, the water, and the sediment microbiota, this kind of multi-habitat selection situation might have had a relevant role in the first event of resistance acquisition by bacterial pathogens³. In favor of this possibility is the finding that *Shewanella*, a waterborne organism, is likely the origin of antibiotic resistance determinants such as QnrA¹⁰² or carbapenem-hydrolyzing oxacillinases¹⁰³, which are now widespread among human pathogens.

Effect of subinhibitory concentrations of antibiotics on bacterial populations

Most studies on the effect of antibiotics on bacterial populations focus on inhibitory concentrations of the drugs. However, most populations confronted with antibiotics are challenged by subinhibitory concentrations of them. The study of the effect of such concentrations has shown that they can have deep effects on bacterial physiology. Indeed, in addition to triggering the expression of shock-response systems^{104–107}, the antibiotics can induce specific bacterial responses. Some of them, dealing with the expression of virulence factors or motility, are specific to each family of drugs³⁶; however, some others seem to be more general. One of them is biofilm formation, which has been described to be triggered by different antibiotics^{36,108–111}. Since biofilms are more resistant to the action of antibiotics, it seems that this can be a protective response. In addition, it is important to remark that

these physiological alterations may improve the bacterial colonization of surfaces. This improvement might have consequences for human health in the case of surface-associated infections (catheters, prosthesis, bladder, lung, etc.) and could also be relevant in natural ecosystems and in industries in which clogged pipelines can be problematic. All of these effects are transient and will disappear soon after removal of the antibiotic. However, even transient effects might produce an inheritable wave. It has been shown that antibiotics can increase mutation, recombination, gene transfer, and prophage induction, all of which have inheritable consequences^{112–121}. Of course, to be evolutionarily relevant, these changes need to be fixed, and fixation is achieved only if bacteria are under selection. In this regard, although subinhibitory concentrations of antibiotics are not always considered to be direct drivers of evolution, it has been proposed that they can increase the evolvability of bacterial populations^{117,122}.

This panorama has changed in the last few years. The classical view indicates that the selection of resistance can happen in a range of concentrations from the minimal inhibitory concentration, under which susceptible and resistant bacteria will grow, to the minimal preventive concentration, which inhibits the growth of resistant mutants. However, recent information indicates that subinhibitory concentrations of antibiotics can select antibiotic-resistant microorganisms^{123–125}. While selection at high concentrations of antibiotics is based on the inhibition of the susceptible cells and hence a resistant population can be selected after few duplication events, both susceptible and resistant microorganisms grow at subinhibitory concentrations and selection is based on the differential fitness they present in the presence of the antimicrobial. This means that the selection of resistance requires, in this case, several duplications to allow the displacement of the susceptible population by the resistant one, which is fitter in the presence of an antibiotic. While it is true that there are several situations in which bacteria are under subinhibitory concentration, such as in the human body after treatment, these concentrations tend to be transient and it is difficult for a resistant population to be selected unless a constant selection pressure is implemented. There are, however, some situations in which this type of selection can be foreseen. One is in waste-water from hospitals or from antibiotic-producing plants. Another is in animal production when antibiotics are used as growth promoters. Indeed, the study of the metagenomes of pigs treated with antibiotics for long periods of time has shown their guts present an increase in Proteobacteria as well as in abundance and diversity of resistance genes, even some of them conferring resistance to antibiotics not administered in the study¹²⁶. These results raise the possibility that non-therapeutic use of antibiotics can be a major element in the selection of antibiotic-resistant bacteria in animals, which will eventually be more important than their therapeutic use.

Work on the effect of antibiotics on the behavior of bacterial populations usually takes into consideration just the antibiotic itself. However, recent work has shown that the presence of other stressors may modulate such effects. Usually, a second stressor increases the chances of acquiring resistance, but on other occasions the stressor antagonizes the selective pressure of the

antibiotic¹²⁷. In the case of human health, this is particularly relevant when resistance to one antibiotic enhances the susceptibility to another (collateral sensitivity) because the use of such antibiotics together or in combination should reduce the chances of antibiotic resistance acquisition by human pathogens^{128–130}.

Competing interests

The author declares that he has no competing interests.

Grant information

The author's laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness (BIO2014-54507-R and JPI Water StARE JPIW2013-089-C02-01) and from the Instituto de Salud Carlos III (Spanish Network for Research on Infectious Diseases [RD16/0016/0011]).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Economou V, Gousia P: **Agriculture and food animals as a source of antimicrobial-resistant bacteria.** *Infect Drug Resist.* 2015; 8: 49–61. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Aarestrup FM: **Veterinary drug usage and antimicrobial resistance in bacteria of animal origin.** *Basic Clin Pharmacol Toxicol.* 2005; 96(4): 271–81. [PubMed Abstract](#) | [Publisher Full Text](#)
- Cabello FC, Godfrey HP, Tomova A, *et al.*: **Antimicrobial use in aquaculture re-examined: its relevance to antimicrobial resistance and to animal and human health.** *Environ Microbiol.* 2013; 15(7): 1917–42. [PubMed Abstract](#) | [Publisher Full Text](#)
- Cabello FC: **Heavy use of prophylactic antibiotics in aquaculture: a growing problem for human and animal health and for the environment.** *Environ Microbiol.* 2006; 8(7): 1137–44. [PubMed Abstract](#) | [Publisher Full Text](#)
- Berendonk TU, Manaia CM, Merlin C, *et al.*: **Tackling antibiotic resistance: the environmental framework.** *Nat Rev Microbiol.* 2015; 13(5): 310–7. [PubMed Abstract](#) | [Publisher Full Text](#)
- Bush K, Courvalin P, Dantas G, *et al.*: **Tackling antibiotic resistance.** *Nat Rev Microbiol.* 2011; 9(12): 894–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Laxminarayan R, Duse A, Wattal C, *et al.*: **Antibiotic resistance—the need for global solutions.** *Lancet Infect Dis.* 2013; 13(12): 1057–98. [PubMed Abstract](#) | [Publisher Full Text](#)
- Holmes AH, Moore LS, Sundsfjord A, *et al.*: **Understanding the mechanisms and drivers of antimicrobial resistance.** *Lancet.* 2016; 387(10014): 176–87. [PubMed Abstract](#) | [Publisher Full Text](#)
- Martinez JL: **Antibiotics and antibiotic resistance genes in natural environments.** *Science.* 2008; 321(5887): 365–7. [PubMed Abstract](#) | [Publisher Full Text](#)
- Sommer MO, Dantas G: **Antibiotics and the resistant microbiome.** *Curr Opin Microbiol.* 2011; 14(5): 556–63. [PubMed Abstract](#) | [Publisher Full Text](#)
- Loft T, Allen HK: **Collateral effects of antibiotics on mammalian gut microbiomes.** *Gut Microbes.* 2012; 3(5): 463–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jernberg C, Lofmark S, Edlund C, *et al.*: **Long-term impacts of antibiotic exposure on the human intestinal microbiota.** *Microbiology.* 2010; 156(1): 3216–23. [PubMed Abstract](#) | [Publisher Full Text](#)
- Raymond F, Deraspe M, Boissinot M, *et al.*: **Partial recovery of microbiomes after antibiotic treatment.** *Gut Microbes.* 2016; 7(5): 428–34. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hu Y, Yang X, Qin J, *et al.*: **Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota.** *Nat Commun.* 2013; 4: 2151. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ghosh TS, Gupta SS, Nair GB, *et al.*: **In silico analysis of antibiotic resistance genes in the gut microflora of individuals from diverse geographies and age-groups.** *PLoS One.* 2013; 8(12): e83823. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Forslund K, Sunagawa S, Kultima JR, *et al.*: **Country-specific antibiotic use practices impact the human gut resistome.** *Genome Res.* 2013; 23(7): 1163–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Sommer MO, Dantas G, Church GM: **Functional characterization of the antibiotic resistance reservoir in the human microflora.** *Science.* 2009; 325(5944): 1128–31. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Robinson CJ, Young VB: **Antibiotic administration alters the community structure of the gastrointestinal microbiota.** *Gut Microbes.* 2010; 1(4): 279–84. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Whangbo J, Ritz J, Bhatt A: **Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation.** *Bone Marrow Transplant.* 2016. [PubMed Abstract](#) | [Publisher Full Text](#)
- Rosser EC, Mauri C: **A clinical update on the significance of the gut microbiota in systemic autoimmunity.** *J Autoimmun.* 2016; 74: 85–93. [PubMed Abstract](#) | [Publisher Full Text](#)
- Ianiro G, Tilg H, Gasbarrini A: **Antibiotics as deep modulators of gut microbiota: between good and evil.** *Gut.* 2016; pii: gutjnl-2016-312297. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Ferrer M, Méndez-García C, Rojo D, *et al.*: **Antibiotic use and microbiome function.** *Biochem Pharmacol.* 2016; pii: S0006-2952(16)30286-6. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- F** de Gunzburg J, Ducher A, Modest C, *et al.*: **Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.** *J Clin Pharmacol.* 2015; 55(1): 10–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Wellington EM, Boxall AB, Cross P, *et al.*: **The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria.** *Lancet Infect Dis.* 2013; 13(2): 155–65. [PubMed Abstract](#) | [Publisher Full Text](#)
- Martinez JL, Fajardo A, Garmendia L, *et al.*: **A global view of antibiotic resistance.** *FEMS Microbiol Rev.* 2009; 33(1): 44–65. [PubMed Abstract](#) | [Publisher Full Text](#)
- Fajardo A, Linares JF, Martinez JL: **Towards an ecological approach to antibiotics and antibiotic resistance genes.** *Clin Microbiol Infect.* 2009; 15(Suppl 1): 14–6. [PubMed Abstract](#) | [Publisher Full Text](#)
- Baquero F, Alvarez-Ortega C, Martinez JL: **Ecology and evolution of antibiotic resistance.** *Environ Microbiol Rep.* 2009; 1(6): 469–76. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Cleary DW, Bishop AH, Zhang L, *et al.*: **Long-term antibiotic exposure in soil is associated with changes in microbial community structure and prevalence of class 1 integrons.** *FEMS Microbiol Ecol.* 2016; 92(10): pii: fiw159. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Gaze WH, Zhang L, Abdoulsalam NA, *et al.*: **Impacts of anthropogenic activity on the ecology of class 1 integrons and integron-associated genes in the environment.** *ISME J.* 2011; 5(8): 1253–61. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- F** Amos GC, Gozzard E, Carter CE, *et al.*: **Validated predictive modelling of the environmental resistome.** *ISME J.* 2015; 9(6): 1467–76. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Roca I, Akova M, Baquero F, *et al.*: **The global threat of antimicrobial resistance: science for intervention.** *New Microbes New Infect.* 2015; 6: 22–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kotzerke A, Sharma S, Schauss K, *et al.*: **Alterations in soil microbial activity and N-transformation processes due to sulfadiazine loads in pig-manure.** *Environ Pollut.* 2008; 153(2): 315–22. [PubMed Abstract](#) | [Publisher Full Text](#)
- F** Roose-Amsaleg C, Laverman AM: **Do antibiotics have environmental side-effects? Impact of synthetic antibiotics on biogeochemical processes.** *Environ Sci Pollut Res Int.* 2016; 23(5): 4000–12. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- F** Liu A, Cao H, Yang Y, *et al.*: **Combinational effects of sulfamethoxazole and copper on soil microbial community and function.** *Environ Sci Pollut Res Int.* 2016; 23(5): 4235–41. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

35. **F** Katipoglu-Yazan T, Merlin C, Pons MN, *et al.*: **Chronic impact of tetracycline on nitrification kinetics and the activity of enriched nitrifying microbial culture.** *Water Res.* 2015; **72**: 227–38.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. **F** Linares JF, Gustafsson I, Baquero F, *et al.*: **Antibiotics as intermicrobial signaling agents instead of weapons.** *Proc Natl Acad Sci U S A.* 2006; **103**(51): 19484–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
37. Yim G, Wang HH, Davies J: **Antibiotics as signalling molecules.** *Philos Trans R Soc Lond B Biol Sci.* 2007; **362**(1483): 1195–200.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Yim G, Wang HH, Davies J: **The truth about antibiotics.** *Int J Med Microbiol.* 2006; **296**(2–3): 163–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Yim G, de La Cruz F, Spiegelman GB, *et al.*: **Transcription modulation of *Salmonella enterica* serovar Typhimurium promoters by sub-MIC levels of rifampin.** *J Bacteriol.* 2006; **188**(22): 7988–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Waksman SA, Woodruff HB: **The Soil as a Source of Microorganisms Antagonistic to Disease-Producing Bacteria.** *J Bacteriol.* 1940; **40**(4): 581–600.
[PubMed Abstract](#) | [Free Full Text](#)
41. Pesci EC, Milbank JB, Pearson JP, *et al.*: **Quinolone signaling in the cell-to-cell communication system of *Pseudomonas aeruginosa*.** *Proc Natl Acad Sci U S A.* 1999; **96**(20): 11229–34.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. **F** Dantas G, Sommer MO, Oluwasegun RD, *et al.*: **Bacteria subsisting on antibiotics.** *Science.* 2008; **320**(5872): 100–3.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
43. Davies J, Spiegelman GB, Yim G: **The world of subinhibitory antibiotic concentrations.** *Curr Opin Microbiol.* 2006; **9**(5): 445–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Calabrese EJ: **Paradigm lost, paradigm found: the re-emergence of hormesis as a fundamental dose response model in the toxicological sciences.** *Environ Pollut.* 2005; **138**(3): 379–411.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Calabrese EJ: **Hormesis: a revolution in toxicology, risk assessment and medicine.** *EMBO Rep.* 2004; **5**(Spec No): S37–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Fajardo A, Martinez JL: **Antibiotics as signals that trigger specific bacterial responses.** *Curr Opin Microbiol.* 2008; **11**(2): 161–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. **F** Kelsic ED, Zhao J, Vetsigian K, *et al.*: **Counteraction of antibiotic production and degradation stabilizes microbial communities.** *Nature.* 2015; **521**(7553): 516–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
48. Baquero F, Martinez J, Cantón R: **Antibiotics and antibiotic resistance in water environments.** *Curr Opin Biotechnol.* 2008; **19**(3): 260–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Olivares J, Bernardini A, Garcia-Leon G, *et al.*: **The intrinsic resistome of bacterial pathogens.** *Front Microbiol.* 2013; **4**: 103.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Cox G, Wright GD: **Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions.** *Int J Med Microbiol.* 2013; **303**(6–7): 287–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Girgis HS, Hottes AK, Tavazois S: **Genetic architecture of intrinsic antibiotic susceptibility.** *PLoS One.* 2009; **4**(5): e5629.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. **F** Abeles SR, Jones MB, Santiago-Rodriguez TM, *et al.*: **Microbial diversity in individuals and their household contacts following typical antibiotic courses.** *Microbiome.* 2016; **4**(1): 39.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
53. **F** Zhang Y, Tian Z, Liu M, *et al.*: **High Concentrations of the Antibiotic Spiramycin in Wastewater Lead to High Abundance of Ammonia-Oxidizing Archaea in Nitrifying Populations.** *Environ Sci Technol.* 2015; **49**(15): 9124–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
54. **F** Schwab EM, Wilkes J, Korgenski K, *et al.*: **Risk Factors for Recurrent *Clostridium difficile* Infection in Pediatric Inpatients.** *Hosp Pediatr.* 2016; **6**(6): 339–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
55. Ramos A, Ortiz J, Asensio Á, *et al.*: **Risk Factors for *Clostridium difficile* Diarrhea in Patients With Solid Organ Transplantation.** *Prog Transplant.* 2016; **26**(3): 231–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. **F** Milani C, Ticinesi A, Gerritsen J, *et al.*: **Gut microbiota composition and *Clostridium difficile* infection in hospitalized elderly individuals: a metagenomic study.** *Sci Rep.* 2016; **6**: 25945.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
57. **F** Youngster I, Mahabamunuge J, Systrom HK, *et al.*: **Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent *Clostridium difficile* infection.** *BMC Med.* 2016; **14**(1): 134.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
58. **F** Kelly CR, Khoruts A, Staley C, *et al.*: **Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent *Clostridium difficile* Infection: A Randomized Trial.** *Ann Intern Med.* 2016; **165**(9): 609–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
59. **F** Fischer M, Kao D, Kelly C, *et al.*: **Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory *Clostridium difficile* Infection in Patients with Inflammatory Bowel Disease.** *Inflamm Bowel Dis.* 2016; **22**(10): 2402–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
60. **F** Chapman BC, Moore HB, Overbey DM, *et al.*: **Fecal microbiota transplant in patients with *Clostridium difficile* infection: A systematic review.** *J Trauma Acute Care Surg.* 2016; **81**(4): 756–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
61. Baquero F, Coque TM, Cantón R: **Allodemics.** *Lancet Infect Dis.* 2002; **2**(10): 591–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Baquero F: **From pieces to patterns: evolutionary engineering in bacterial pathogens.** *Nat Rev Microbiol.* 2004; **2**(6): 510–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
63. Baquero F, Coque TM: **Multilevel population genetics in antibiotic resistance.** *FEMS Microbiol Rev.* 2011; **35**(5): 705–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Martínez JL, Coque TM, Baquero F: **Prioritizing risks of antibiotic resistance genes in all metagenomes.** *Nat Rev Microbiol.* 2015; **13**(6): 396.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Martínez JL, Coque TM, Baquero F: **What is a resistance gene? Ranking risk in resistomes.** *Nat Rev Microbiol.* 2015; **13**(2): 116–23.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Martínez JL: **Natural antibiotic resistance and contamination by antibiotic resistance determinants: the two ages in the evolution of resistance to antimicrobials.** *Front Microbiol.* 2012; **3**: 1.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
67. Aineberg J, Bjarnason BS, de Bruijn I, *et al.*: **Binning metagenomic contigs by coverage and composition.** *Nat Methods.* 2014; **11**(11): 1144–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. Imelfort M, Parks D, Woodcroft BJ, *et al.*: **GroopM: an automated tool for the recovery of population genomes from related metagenomes.** *PeerJ.* 2014; **2**: e603.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
69. Strous M, Kraft B, Bisdorf R, *et al.*: **The binning of metagenomic contigs for microbial physiology of mixed cultures.** *Front Microbiol.* 2012; **3**: 410.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
70. Kelley DR, Salzberg SL: **Clustering metagenomic sequences with interpolated Markov models.** *BMC Bioinformatics.* 2010; **11**: 544.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Wu Y, Simmons BA, Singer SW: **MaxBin 2.0: an automated binning algorithm to recover genomes from multiple metagenomic datasets.** *Bioinformatics.* 2016; **32**(4): 605–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Kang DD, Froula J, Egan R, *et al.*: **MetaBAT, an efficient tool for accurately reconstructing single genomes from complex microbial communities.** *PeerJ.* 2015; **3**: e1165.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. Spencer SJ, Tamminen MV, Preheim SP, *et al.*: **Massively parallel sequencing of single cells by epicPCR links functional genes with phylogenetic markers.** *ISME J.* 2016; **10**(2): 427–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Martínez JL: **The role of natural environments in the evolution of resistance traits in pathogenic bacteria.** *Proc Biol Sci.* 2009; **276**(1667): 2521–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Martínez JL: **Environmental pollution by antibiotics and by antibiotic resistance determinants.** *Environ Pollut.* 2009; **157**(11): 2893–902.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Martínez JL, Baquero F, Andersson DI: **Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics.** *Curr Opin Pharmacol.* 2011; **11**(5): 439–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. **F** Andersson DI, Hughes D: **Antibiotic resistance and its cost: is it possible to reverse resistance?** *Nat Rev Microbiol.* 2010; **8**(4): 260–71.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
78. **F** Schaefer K, Semmler T, Pickard DJ, *et al.*: **Carriage of Extended-Spectrum Beta-Lactamase-Plasmids Does Not Reduce Fitness but Enhances Virulence in Some Strains of Pandemic *E. coli* Lineages.** *Front Microbiol.* 2016; **7**: 336.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
79. Olivares J, Álvarez-Ortega C, Martínez JL: **Metabolic compensation of fitness costs associated with overexpression of the multidrug efflux pump MexEF-OprN in *Pseudomonas aeruginosa*.** *Antimicrob Agents Chemother.* 2014; **58**(7): 3904–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
80. Schulz zur Wiesch P, Engelstädter J, Bonhoeffer S: **Compensation of fitness costs and reversibility of antibiotic resistance mutations.** *Antimicrob Agents Chemother.* 2010; **54**(5): 2085–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

81. Andersson DI: **The biological cost of mutational antibiotic resistance: any practical conclusions?** *Curr Opin Microbiol.* 2006; 9(5): 461–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. **F** Fitzpatrick D, Walsh F: **Antibiotic resistance genes across a wide variety of metagenomes.** *FEMS Microbiol Ecol.* 2016; 92(2): pii: fiv168.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
83. Walsh F: **Investigating antibiotic resistance in non-clinical environments.** *Front Microbiol.* 2013; 4: 19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. **F** Sousa M, Silva N, Igrejas G, *et al.*: **Genetic Diversity and Antibiotic Resistance Among Coagulase-Negative Staphylococci Recovered from Birds of Prey in Portugal.** *Microb Drug Resist.* 2016; 22(8): 727–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
85. **F** Lyimo B, Buza J, Subbiah M, *et al.*: **IncF Plasmids Are Commonly Carried by Antibiotic Resistant *Escherichia coli* Isolated from Drinking Water Sources in Northern Tanzania.** *Int J Microbiol.* 2016; 2016: 3103672.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
86. **F** Himsforth CG, Zabek E, Desruisseau A, *et al.*: **Avian Pathogenicity Genes and Antibiotic Resistance in *Escherichia coli* Isolates from Wild Norway Rats (*Rattus norvegicus*) in British Columbia, Canada.** *J Wildl Dis.* 2016; 52(2): 418–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
87. **F** Dudzic A, Urban-Chmiel R, Stępień-Pyśniak D, *et al.*: **Isolation, identification and antibiotic resistance of *Campylobacter* strains isolated from domestic and free-living pigeons.** *Br Poult Sci.* 2016; 57(2): 172–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
88. **F** Alonso CA, González-Barrio D, Tenorio C, *et al.*: **Antimicrobial resistance in faecal *Escherichia coli* isolates from farmed red deer and wild small mammals. Detection of a multiresistant *E. coli* producing extended-spectrum beta-lactamase.** *Comp Immunol Microbiol Infect Dis.* 2016; 45: 34–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
89. **F** Power ML, Samuel A, Smith JJ, *et al.*: ***Escherichia coli* out in the cold: Dissemination of human-derived bacteria into the Antarctic microbiome.** *Environ Pollut.* 2016; 215: 58–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
90. Segawa T, Takeuchi N, Rivera A, *et al.*: **Distribution of antibiotic resistance genes in glacier environments.** *Environ Microbiol Rep.* 2013; 5(1): 127–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Miller RV, Gammon K, Day MJ: **Antibiotic resistance among bacteria isolated from seawater and penguin fecal samples collected near Palmer Station, Antarctica.** *Can J Microbiol.* 2009; 55(1): 37–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
92. Durso LM, Miller DN, Wienhold BJ: **Distribution and quantification of antibiotic resistant genes and bacteria across agricultural and non-agricultural metagenomes.** *PLoS One.* 2012; 7(1): e48325.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. **F** Reuland EA, Sonder GJ, Stolte I, *et al.*: **Travel to Asia and traveller's diarrhoea with antibiotic treatment are independent risk factors for acquiring ciprofloxacin-resistant and extended spectrum β -lactamase-producing *Enterobacteriaceae* a prospective cohort study.** *Clin Microbiol Infect.* 2016; 22(8): 731.e1–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
94. **F** Lane CR, Sutton B, Valcanis M, *et al.*: **Travel Destinations and Sexual Behavior as Indicators of Antibiotic Resistant *Shigella* Strains—Victoria, Australia.** *Clin Infect Dis.* 2016; 62(6): 722–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
95. Middleton JH, Ambrose A: **Enumeration and antibiotic resistance patterns of fecal indicator organisms isolated from migratory Canada geese (*Branta canadensis*).** *J Wildl Dis.* 2005; 41(2): 334–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. **F** Poeta P, Radhouani H, Igrejas G, *et al.*: **Seagulls of the Berlengas natural reserve of Portugal as carriers of fecal *Escherichia coli* harboring CTX-M and TEM extended-spectrum beta-lactamases.** *Appl Environ Microbiol.* 2008; 74(23): 7439–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
97. Martínez-Urtaza J, Trínanes J, González-Escalona N, *et al.*: **Is El Niño a long-distance corridor for waterborne disease?** *Nat Microbiol.* 2016; 1: 16018.
[PubMed Abstract](#) | [Publisher Full Text](#)
98. Datta N, Hughes VM: **Plasmids of the same Inc groups in *Enterobacteria* before and after the medical use of antibiotics.** *Nature.* 1983; 306(5943): 616–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
99. Davies J, Davies D: **Origins and evolution of antibiotic resistance.** *Microbiol Mol Biol Rev.* 2010; 74(3): 417–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
100. Allen HK, Donato J, Wang HH, *et al.*: **Call of the wild: antibiotic resistance genes in natural environments.** *Nat Rev Microbiol.* 2010; 8(4): 251–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
101. Martínez JL, Baquero F, Andersson DI: **Predicting antibiotic resistance.** *Nat Rev Microbiol.* 2007; 5(12): 958–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Poirel L, Rodríguez-Martínez J, Mammeri H, *et al.*: **Origin of plasmid-mediated quinolone resistance determinant QnrA.** *Antimicrob Agents Chemother.* 2005; 49(8): 3523–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
103. Poirel L, Héritier C, Nordmann P: **Chromosome-encoded ambl class D beta-lactamase of *Shewanella oneidensis* as a progenitor of carbapenem-hydrolyzing oxacillinase.** *Antimicrob Agents Chemother.* 2004; 48(1): 348–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Bernardini A, Corona F, Dias R, *et al.*: **The inactivation of RNase G reduces the *Stenotrophomonas maltophilia* susceptibility to quinolones by triggering the heat shock response.** *Front Microbiol.* 2015; 6: 1068.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
105. Cardoso K, Gandra RF, Wisniewski ES, *et al.*: **DnaK and GroEL are induced in response to antibiotic and heat shock in *Acinetobacter baumannii*.** *J Med Microbiol.* 2010; 59(Pt 9): 1061–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Lin JT, Connelly MB, Amolo C, *et al.*: **Global transcriptional response of *Bacillus subtilis* to treatment with subinhibitory concentrations of antibiotics that inhibit protein synthesis.** *Antimicrob Agents Chemother.* 2005; 49(5): 1915–26.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Ng WL, Kazmierczak KM, Robertson GT, *et al.*: **Transcriptional regulation and signature patterns revealed by microarray analyses of *Streptococcus pneumoniae* R6 challenged with sublethal concentrations of translation inhibitors.** *J Bacteriol.* 2003; 185(1): 359–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
108. **F** Bleich R, Watrous JD, Dorrestein PC, *et al.*: **Thiopeptide antibiotics stimulate biofilm formation in *Bacillus subtilis*.** *Proc Natl Acad Sci U S A.* 2015; 112(10): 3086–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
109. **F** Aka ST, Haji SH: **Sub-MIC of antibiotics induced biofilm formation of *Pseudomonas aeruginosa* in the presence of chlorhexidine.** *Braz J Microbiol.* 2015; 46(1): 149–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
110. **F** Ng M, Epstein SB, Callahan MT, *et al.*: **Induction of MRSA Biofilm by Low-Dose β -Lactam Antibiotics: Specificity, Prevalence and Dose-Response Effects.** *Dose Response.* 2014; 12(1): 152–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
111. **F** Kaplan JB, Izano EA, Gopal P, *et al.*: **Low levels of β -lactam antibiotics induce extracellular DNA release and biofilm formation in *Staphylococcus aureus*.** *MBio.* 2012; 3(4): e00198–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
112. López E, Blázquez J: **Effect of subinhibitory concentrations of antibiotics on intrachromosomal homologous recombination in *Escherichia coli*.** *Antimicrob Agents Chemother.* 2009; 53(8): 3411–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. **F** López E, Elez M, Matic I, *et al.*: **Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in *Escherichia coli*.** *Mol Microbiol.* 2007; 64(1): 83–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
114. Gutierrez A, Laureti L, Crussard S, *et al.*: **β -Lactam antibiotics promote bacterial mutagenesis via an RpoS-mediated reduction in replication fidelity.** *Nat Commun.* 2013; 4: 1610.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Alonso A, Campanario E, Martínez JL: **Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in *Pseudomonas aeruginosa*.** *Microbiology.* 1999; 145(Pt 10): 2857–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
116. Rodríguez-Rojas A, Rodríguez-Beltrán J, Couce A, *et al.*: **Antibiotics and antibiotic resistance: a bitter fight against evolution.** *Int J Med Microbiol.* 2013; 303(6–7): 293–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
117. Blázquez J, Couce A, Rodríguez-Beltrán J, *et al.*: **Antimicrobials as promoters of genetic variation.** *Curr Opin Microbiol.* 2012; 15(5): 561–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Couce A, Blázquez J: **Side effects of antibiotics on genetic variability.** *FEMS Microbiol Rev.* 2009; 33(3): 531–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
119. Ohlsen K, Ternes T, Werner G, *et al.*: **Impact of antibiotics on conjugational resistance gene transfer in *Staphylococcus aureus* in sewage.** *Environ Microbiol.* 2003; 5(8): 711–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
120. **F** Ubeda C, Maiques E, Knecht E, *et al.*: **Antibiotic-induced SOS response promotes horizontal dissemination of pathogenicity island-encoded virulence factors in staphylococci.** *Mol Microbiol.* 2005; 56(3): 836–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
121. Zhang X, McDaniel AD, Wolf LE, *et al.*: **Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice.** *J Infect Dis.* 2000; 181(2): 664–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
122. Gillings MR, Stokes HW: **Are humans increasing bacterial evolvability?** *Trends*

- Ecol Evol.* 2012; **27**(6): 346–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
123. Hughes D, Andersson DI: **Selection of resistance at lethal and non-lethal antibiotic concentrations.** *Curr Opin Microbiol.* 2012; **15**(5): 555–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 124. Andersson DI, Hughes D: **Evolution of antibiotic resistance at non-lethal drug concentrations.** *Drug Resist Updat.* 2012; **15**(3): 162–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 125. Gullberg E, Cao S, Berg OG, *et al.*: **Selection of resistant bacteria at very low antibiotic concentrations.** *PLoS Pathog.* 2011; **7**(7): e1002158.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 126. Looft T, Johnson TA, Allen HK, *et al.*: **In-feed antibiotic effects on the swine intestinal microbiome.** *Proc Natl Acad Sci U S A.* 2012; **109**(5): 1691–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 127. Chait R, Palmer AC, Yelin I, *et al.*: **Pervasive selection for and against antibiotic resistance in inhomogeneous multistress environments.** *Nat Commun.* 2016; **7**: 10333.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 128. Imamovic L, Sommer MO: **Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development.** *Sci Transl Med.* 2013; **5**(204): 204ra132.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 129. Lázár V, Pal Singh G, Spohn R, *et al.*: **Bacterial evolution of antibiotic hypersensitivity.** *Mol Syst Biol.* 2013; **9**(1): 700.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 130. Baym M, Stone LK, Kishony R: **Multidrug evolutionary strategies to reverse antibiotic resistance.** *Science.* 2016; **351**(6268): aad3292.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Ivan Matic**

Faculté de Médecine Paris Descartes, Université Paris Descartes, Paris, France

Competing Interests: No competing interests were disclosed.

2. **Søren Molin**

Department of Systems Biology, Danmarks Tekniske Universitet, Lyngby, DK-2800, Denmark

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research